These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 14973554)

  • 21. Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells.
    Liau SS; Jazag A; Ito K; Whang EE
    Br J Cancer; 2007 Mar; 96(6):993-1000. PubMed ID: 17342093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis.
    Taddei ML; Parri M; Angelucci A; Onnis B; Bianchini F; Giannoni E; Raugei G; Calorini L; Rucci N; Teti A; Bologna M; Chiarugi P
    Am J Pathol; 2009 Apr; 174(4):1492-503. PubMed ID: 19264906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of the PI3K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas.
    Lu XS; Sun W; Ge CY; Zhang WZ; Fan YZ
    Int J Oncol; 2013 Jun; 42(6):2103-15. PubMed ID: 23588386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma.
    Liau SS; Rocha F; Matros E; Redston M; Whang E
    Cancer; 2008 Jul; 113(2):302-14. PubMed ID: 18473350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.
    Nishimura M; Jung EJ; Shah MY; Lu C; Spizzo R; Shimizu M; Han HD; Ivan C; Rossi S; Zhang X; Nicoloso MS; Wu SY; Almeida MI; Bottsford-Miller J; Pecot CV; Zand B; Matsuo K; Shahzad MM; Jennings NB; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Calin GA
    Cancer Discov; 2013 Nov; 3(11):1302-15. PubMed ID: 24002999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RNA interference targeting EphA2 inhibits proliferation, induces apoptosis, and cooperates with cytotoxic drugs in human glioma cells.
    Zhou Z; Yuan X; Li Z; Tu H; Li D; Qing J; Wang H; Zhang L
    Surg Neurol; 2008 Dec; 70(6):562-8; discussion 568-9. PubMed ID: 18614215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anchorage-independent phosphorylation of p130(Cas) protects lung adenocarcinoma cells from anoikis.
    Wei L; Yang Y; Zhang X; Yu Q
    J Cell Biochem; 2002; 87(4):439-49. PubMed ID: 12397603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
    Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
    Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation.
    Miao H; Burnett E; Kinch M; Simon E; Wang B
    Nat Cell Biol; 2000 Feb; 2(2):62-9. PubMed ID: 10655584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting of focal adhesion kinase by flavonoids and small-interfering RNAs reduces tumor cell migration ability.
    Huang YT; Lee LT; Lee PP; Lin YS; Lee MT
    Anticancer Res; 2005; 25(3B):2017-25. PubMed ID: 16158939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer.
    Ansuini H; Meola A; Gunes Z; Paradisi V; Pezzanera M; Acali S; Santini C; Luzzago A; Mori F; Lazzaro D; Ciliberto G; Nicosia A; La Monica N; Vitelli A
    J Oncol; 2009; 2009():951917. PubMed ID: 20130824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of erythropoietin-producing hepatocellular receptor A2 attenuates cell adhesion of human fallopian tube epithelial cells via focal adhesion kinase dephosphorylation.
    Yang XY; Zhu WJ; Jiang H
    Mol Cell Biochem; 2012 Feb; 361(1-2):259-65. PubMed ID: 22009484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Invasion in follicular thyroid cancer cell lines is mediated by EphA2 and pAkt.
    O'Malley Y; Lal G; Howe JR; Weigel RJ; Komorowski RA; Shilyansky J; Sugg SL
    Surgery; 2012 Dec; 152(6):1218-24. PubMed ID: 23158188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma.
    Li X; Wang L; Gu JW; Li B; Liu WP; Wang YG; Zhang X; Zhen HN; Fei Z
    Tumour Biol; 2010 Oct; 31(5):477-88. PubMed ID: 20571968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer.
    Duxbury MS; Matros E; Ito H; Zinner MJ; Ashley SW; Whang EE
    Ann Surg; 2004 Oct; 240(4):667-74; discussion 675-6. PubMed ID: 15383794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
    Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
    Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
    Lu M; Miller KD; Gokmen-Polar Y; Jeng MH; Kinch MS
    Cancer Res; 2003 Jun; 63(12):3425-9. PubMed ID: 12810680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ephexin4 and EphA2 mediate resistance to anoikis through RhoG and phosphatidylinositol 3-kinase.
    Harada K; Hiramoto-Yamaki N; Negishi M; Katoh H
    Exp Cell Res; 2011 Jul; 317(12):1701-13. PubMed ID: 21621533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.
    Garcia-Monclús S; López-Alemany R; Almacellas-Rabaiget O; Herrero-Martín D; Huertas-Martinez J; Lagares-Tena L; Alba-Pavón P; Hontecillas-Prieto L; Mora J; de Álava E; Rello-Varona S; Giangrande PH; Tirado OM
    Int J Cancer; 2018 Sep; 143(5):1188-1201. PubMed ID: 29582409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.
    Chang Q; Jorgensen C; Pawson T; Hedley DW
    Br J Cancer; 2008 Oct; 99(7):1074-82. PubMed ID: 18797457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.